Lazertinib’s US Approval A Catalyst For Oscotec’s Growth

Anti-Resistance, Anti-Tau Therapies Next Focus

 
• By Jung Won Shin
  
Taeyoung Yoon, Oscotec CEO
Long-Term Goal To Grow Into FIPCO With Marketing, Commercial Presence (Oscotec Inc.)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Focus On Asia

More from R&D